Q
Quad Medicine
Microneedle patch platform for transdermal drug delivery
About Quad Medicine
QuadMedicine is a South Korean biotechnology company founded in 2017 by CEO Baek Seung-ki, who has over 15 years of experience in medical device research and development. The company is focused on developing drug delivery technologies centered on its Microneedle Array Patch (MAP) products, which offer a minimally invasive method for delivering drugs through the skin. This approach aims to overcome the limitations of traditional injections and oral medications, such as pain and low absorption rates.
The company's core technology involves a patch with microneedles less than 1 mm in length that efficiently deliver drugs to the dermis. QuadMedicine has developed three main platform technologies: Separable MAP (S-MAP), where the needle tip separates upon administration; Coated MAP (C-MAP), which coats active ingredients onto the microstructures; and Particle-attached MAP (P-MAP). These platforms are designed for versatility and can be applied to various formulations including vaccines, peptides, and synthetic drugs, with benefits such as precise dosing, the potential for room-temperature storage, and the convenience of self-administration.
QuadMedicine's business model incorporates a contract development and manufacturing organization (CDMO) strategy, integrating formulation development with clinical and commercial production. The company has established an aseptic automated microneedle manufacturing process to ensure quality and cost-effectiveness. QuadMedicine collaborates with global pharmaceutical companies on joint development and technology transfer projects. Notable collaborations include a partnership with LG Chem for a hepatitis B vaccine, which was the first in Korea to receive IND approval for a Phase 1 clinical trial using microneedles, and research projects with GSK plc and the RIGHT Foundation. The company's revenue streams are expected to come from milestone technology fees and future royalties from product sales.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Dec 2025 | $21M | — | Undisclosed | — |
| SERIES C✓Equity / VC | May 2022 | $17M | $69M | Kiwoom Investment · NH Investment & Securities | — |
Growth signals
Latest recorded traffic for Quad Medicine is 15K monthly website visits, down 11.8% over the last three months. Quad Medicine's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
TareBioReverse-engineering immune cells for rapid vaccine development. |
San Francisco, United States | Operational | 1 | $125K | $500K |
BayVax BiotechAI-powered immune programming for personalized and broad-spectrum vaccines. |
— | Operational | |||
MSD TaiwanResearch-based development of pharmaceuticals and vaccines. |
— | Operational | |||
SignlSmall molecules decoupling protection from inflammatory side-effects. |
Chicago, United States | Operational | |||
Teichos LaboratoriesSynthetic immune signals for immunotherapy and vaccine development |
Indianapolis, United States | Operational | |||
ImmunoSig Ltd.Immune response profiling via peptide microarray technology |
Manchester, United Kingdom | Operational | |||
IntegerBioPioneering immunology to develop multi-viral therapeutics combating serious viral diseases |
Gaithersburg, United States | Operational | |||
TheraVac BiologicsImmunotherapies for neurodegenerative and chronic diseases |
United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Quad Medicine in the Seongnam-si ecosystem
The Quad Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
SparkLabs Korea
Series B and later2 investors entered at this stage
- KIKiwoom Investment
NH Investment & Securities
Other known investors3 additional known investors
Krypton
Shinhan Venture Investment
SparkLabs Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quad Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quad Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








